StockNews.AI

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

StockNews.AI • 1 minute

NVDAPFENTLA
High Materiality8/10

Information

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OC...

Original source

AI Summary

Ocugen announces OCU410 trial data discussion on January 15, 2026. Key opinion leaders will present results on blindness cessation therapies. The clinical trial could impact millions with inherited retinal diseases. Webcast and replay available for investors post-event. Ocugen's gene therapies target complex disorders with unmet medical needs.

Sentiment Rationale

The conference call may showcase positive trial results, enhancing investor confidence. Historical examples, like favorable clinical trial announcements, often positively influence biotech stock prices, suggesting a potential stock increase.

Trading Thesis

Results from the clinical trial discussion could lead to immediate market reactions. Investors typically react quickly to news about Phase 2 trial results.

Market-Moving

  • Ocugen announces OCU410 trial data discussion on January 15, 2026.
  • Key opinion leaders will present results on blindness cessation therapies.
  • The clinical trial could impact millions with inherited retinal diseases.

Key Facts

  • Ocugen announces OCU410 trial data discussion on January 15, 2026.
  • Key opinion leaders will present results on blindness cessation therapies.
  • The clinical trial could impact millions with inherited retinal diseases.
  • Webcast and replay available for investors post-event.
  • Ocugen's gene therapies target complex disorders with unmet medical needs.

Companies Mentioned

  • NVDA (NVDA)
  • PFE (PFE)
  • NTLA (NTLA)

Corporate Developments

The article highlights significant upcoming information that could alter perceptions about Ocugen's pipeline, making it crucial for stakeholders.

Ocugen to Discuss OCU410 Phase 2 Clinical Trial Data in Upcoming Webcast

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company specializing in gene therapies for blindness diseases, has announced a forthcoming conference call and live webcast. Scheduled for January 15, 2026, at 8:30 a.m. ET, the event will focus on the results of the OCU410 Phase 2 ArMaDa clinical trial, specifically data from patients who have completed one year since their treatment.

Key Details of the Webcast

During the call, key opinion leaders (KOLs) and members of Ocugen's executive team will present the trial findings. The panel will include:

  • Dr. Arshad M. Khanani, MD, MA, FASRS – Director of Clinical Research at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine.
  • Dr. Jay Chhablani, MD – Vitreo-Retina Specialist at the University of Pittsburgh Eye Center.
  • Dr. Lejla Vajzovic, MD, FASRS – Professor of Ophthalmology and Director of CME-Ophthalmology at Duke University School of Medicine.

Participants can join the conference using the following details:

  • U.S. Dial-in Number: (800) 715-9871
  • International Dial-in Number: (646) 307-1963
  • Conference ID: 7783588
  • Webcast: Available on the events section of the Ocugen investor site.

A replay of the call and an archived version of the webcast will be accessible after the event on the Ocugen website.

About Ocugen, Inc.

Ocugen, Inc. is at the forefront of biotechnology, focusing on innovative gene therapies for blindness diseases. Through its unique modifier gene therapy platform, the company aims to meet significant unmet medical needs for large patient populations. Unlike traditional gene therapies that target specific genes, Ocugen’s approach is gene-agnostic, potentially addressing complex diseases caused by multiple gene network imbalances.

The company is developing therapies for various inherited retinal diseases and conditions that cause vision impairment, such as:

  • Retinitis pigmentosa
  • Stargardt disease
  • Geographic atrophy (late-stage dry age-related macular degeneration)

To learn more about Ocugen and its innovative therapies, visit www.ocugen.com and connect with us on LinkedIn and X.

Cautionary Note on Forward-Looking Statements

This announcement contains forward-looking statements as defined by The Private Securities Litigation Reform Act of 1995. The company may use terms such as “predicts,” “believes,” “potential,” “proposed,” “estimates,” “expects,” and other similar phrases to indicate forward-looking statements. These statements involve risks and uncertainties that may cause actual results to differ significantly from expectations.

For detailed risk factors, please review the periodic filings of Ocugen with the Securities and Exchange Commission, particularly the “Risk Factors” section of quarterly and annual reports. Ocugen does not undertake any obligation to update the forward-looking statements made in this press release after its initial release.

Media Contact

Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

Related News